Israel - engelsk - Ministry of Health

j-c health care ltd - ustekinumab - solution for injection - ustekinumab 45 mg / 0.5 ml - ustekinumab - ustekinumab - *plaque psoriasisstelara is indicated for the treatment of moderate to severe plaque psoriasis in adult patients (18 years or older) who have failed to, have a contraindication to, or who are intolerant to other systemic therapies including ciclosporin, methotrexate or psoralen plus u.v (puva) paediatric plaque psoriasisstelara is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from the age of 6 years and older, who are inadequately controlled by, or are intolerant to, othersystemic therapies or phototherapies.psoriatic arthritis (psa)stelara, alone or in combination with mtx, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease modifying anti rheumatic drug (dmard) therapy has been inadequatecrohn’s diseasestelara is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tnfα antagonist or have medical contraindications to such therapies.ulcerative colitisstelara is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies

Israel - engelsk - Ministry of Health

j-c health care ltd - ustekinumab - solution for injection - ustekinumab 45 mg / 0.5 ml - ustekinumab - ustekinumab - plaque psoriasisstelara is indicated for the treatment of moderate to severe plaque psoriasis in adult patients (18 years or older) who have failed to, have a contraindication to, or who are intolerant to other systemic therapies including ciclosporin, methotrexate or psoralen plus u.v (puva) paediatric plaque psoriasisstelara is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from the age of 6 years and older, who are inadequately controlled by, or are intolerant to, othersystemic therapies or phototherapies.psoriatic arthritis (psa)stelara, alone or in combination with mtx, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease modifying anti rheumatic drug (dmard) therapy has been inadequatecrohn’s diseasestelara is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tnfα antagonist or have medical contraindications to such therapies.ulcerative colitisstelara is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies

Israel - engelsk - Ministry of Health

j-c health care ltd - ibrutinib - capsules - ibrutinib 140 mg - • mantle cell lymphoma:imbruvica is indicated for the treatment of adult patients with mantle cell lymphoma (mcl) who have received at least one prior therapy.• chronic lymphocytic leukemia/small lymphocytic lymphoma :imbruvica is indicated for the treatment of adult patients, with chronic lymphocytic leukemia (cll)/small lymphocytic lymphoma (sll)• chronic lymphocytic leukemia (cll) /small lymphocytic lymphoma (sll) with 17p deletion:imbruvica is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll) /small lymphocytic lymphoma (sll) with 17p deletion.• waldenström’s macroglobulinemiaimbruvica is indicated for the treatment of adult patients with waldenström’s macroglobulinemia (wm).• marginal zone lymphomaimbruvica is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who require systemic therapy and have received at least one prior anti-cd20-based therapy.• chronic graft versus host diseaseimbruvica is indicated for the treatment of adult patients with chronic graft-versus-host disease (cgvhd) after failure of one or more lines of systemic therapy.

Israel - engelsk - Ministry of Health

j-c health care ltd - ustekinumab - solution for injection - ustekinumab 45 mg / 0.5 ml - ustekinumab - * pque poriasis stelara is indicated for the treatment of moderate to severe plaque psoriasis in adult patients (18 years or older) who have failed to, or have contraindication to or who are intolerant to other systemic therapies including ciclosporin, methotrexate or psoralen plus u.v (puva).* psoriatic arthritisstelara, alone or in combination with mtx, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug (dmard) therapy has been inadequatepediatric plaque psoriasis:stelara is indicated for the treatment of moderate to severe plaque psoriasis in adolescent patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.* crohn’s disease:stelara is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tnfα antagonist or have medical contraindications to such therapies.

Israel - engelsk - Ministry of Health

j-c health care ltd - decitabine - powder for concentrate for solution for infusion - decitabine 50 mg/vial - decitabine - decitabine - dacogen is indicated for treatment of patients with myelodysplastic syndromes (mds) including previously treated and untreated, de novo and secondary mds of all french-american-british subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2 and high-risk international prognostic scoring system groups. dacogen is indicated for the treatment of adult patients with newly diagnosed de novo or secondary acute myeloid leukemia (aml), according to the world health organisation (who) classification, who are not candidates for standard induction chemotherapy.

Israel - engelsk - Ministry of Health

j-c health care ltd - methylphenidate hydrochloride - tablets extended release - methylphenidate hydrochloride 18 mg - methylphenidate - methylphenidate - concerta is indicated for the treatment of attention deficit hyperactivity disorder (adhd).

Israel - engelsk - Ministry of Health

j-c health care ltd - methylphenidate hydrochloride - tablets extended release - methylphenidate hydrochloride 36 mg - methylphenidate - methylphenidate - concerta is indicated for the treatment of attention deficit hyperactivity disorder (adhd).

Israel - engelsk - Ministry of Health

j-c health care ltd - methylphenidate hydrochloride - tablets extended release - methylphenidate hydrochloride 54 mg - methylphenidate - methylphenidate - concerta is indicated for the treatment of attention deficit hyperactivity disorder (adhd).

Israel - engelsk - Ministry of Health

j-c health care ltd - methylphenidate hydrochloride - tablets extended release - methylphenidate hydrochloride 27 mg - methylphenidate - methylphenidate - concerta is indicated for the treatment of attention deficit hyperactivity disorder (adhd).

Israel - engelsk - Ministry of Health

j-c health care ltd - trolamine - cream - trolamine 0.67 %w/w - soothes burns, sunburns, sores and wounds.